$150
per visit
24 weeks
Duration
8
Total Visits
102
Spots Remaining
About This Study
This study investigates a new oral JAK inhibitor for patients with rheumatoid arthritis who have not adequately responded to methotrexate. The once-daily pill targets specific enzymes involved in joint inflammation.
Study Objectives
To evaluate the proportion of patients achieving ACR50 response at week 12.
Eligibility Requirements
Inclusion Criteria
- Adults 18-75 years old
- Diagnosis of rheumatoid arthritis for at least 6 months
- Active disease despite methotrexate therapy
- At least 4 tender and 4 swollen joints
- Elevated inflammatory markers
Exclusion Criteria
- Prior JAK inhibitor use
- Active or chronic infections
- History of blood clots
- Severe liver or kidney disease
Frequently Asked Questions
Study Location
University of Washington Medical Center
Seattle, WA 98195
Map View
Research Team
Dr. Robert Kim
University of Washington
Rheumatology Research
Study Timeline
Start DateMarch 15, 2024
End DateMarch 15, 2025
Enrollment98 / 200